A Role for Cytosolic Fumarate Hydratase in Urea Cycle Metabolism and Renal Neoplasia by Adam, J. et al.
 
 
University of Birmingham
A Role for Cytosolic Fumarate Hydratase in Urea
Cycle Metabolism and Renal Neoplasia
Adam, J.; Yang, M.; Bauerschmidt, C.; O'Flaherty, L.; Maheswaran, P.; Özkan, G.; Pollard,
P.J.; Pugh, C.; Ratcliffe, P.J.; Kitagawa, M.; Kato, K.; Saito, K.; Iino, K.; Igarashi, K.; Soga, T.;
Sahgal, N.; Baban, D.; Davies, B.; Stratford, M.; Tennant, D.A.
DOI:
10.1016/j.celrep.2013.04.006
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Adam, J, Yang, M, Bauerschmidt, C, O'Flaherty, L, Maheswaran, P, Özkan, G, Pollard, PJ, Pugh, C, Ratcliffe,
PJ, Kitagawa, M, Kato, K, Saito, K, Iino, K, Igarashi, K, Soga, T, Sahgal, N, Baban, D, Davies, B, Stratford, M,
Tennant, DA, Ludwig, C, El-Bahrawy, M & Ashrafian, H 2013, 'A Role for Cytosolic Fumarate Hydratase in Urea
Cycle Metabolism and Renal Neoplasia', Cell Reports, vol. 3, no. 5, pp. 1440-1448.
https://doi.org/10.1016/j.celrep.2013.04.006
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Published under a Creative Commons Attribution license
Checked September 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Cell Reports
ReportA Role for Cytosolic Fumarate Hydratase
in Urea Cycle Metabolism and Renal Neoplasia
Julie Adam,1 Ming Yang,1,14 Christina Bauerschmidt,1,14 Mitsuhiro Kitagawa,4,14 Linda O’Flaherty,1,14
Pratheesh Maheswaran,1 Gizem O¨zkan,1 Natasha Sahgal,6 Dilair Baban,7 Keiko Kato,4 Kaori Saito,4 Keiko Iino,4
Kaori Igarashi,4 Michael Stratford,9 Christopher Pugh,2 Daniel A. Tennant,10 Christian Ludwig,10 Benjamin Davies,8
Peter J. Ratcliffe,2 Mona El-Bahrawy,11,12 Houman Ashrafian,13 Tomoyoshi Soga,4,5 and Patrick J. Pollard1,3,*
1Cancer Biology and Metabolism Group
2Hypoxia Biology Group
3Oxford-Keio Metabolomics Consortium
Nuffield Department of Medicine, Henry Wellcome Building for Molecular Physiology, University of Oxford, Oxford OX3 7BN, UK
4Institute for Advanced Biosciences
5Oxford-Keio Metabolomics Consortium
Keio University, 246-2 Mizukami, Tsuruoka, Yamagata 997-0052, Japan
6Bioinformatics and Statistical Genetics
7High Throughput Genomics
8Transgenic Core
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
9Gray Institute for Radiation Oncology and Biology, Department of Oncology, Old Road Campus Research Building, University of Oxford,
Roosevelt Drive, Oxford OX3 7DQ, UK
10School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
11Department of Histopathology, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
12Department of Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
13Department of Cardiovascular Medicine, University of Oxford, Oxford OX3 9DU, UK
14These authors contributed equally to this work
*Correspondence: paddy@well.ox.ac.uk
http://dx.doi.org/10.1016/j.celrep.2013.04.006SUMMARY
The identification of mutated metabolic enzymes in
hereditary cancer syndromes has established a
direct link betweenmetabolic dysregulation and can-
cer. Mutations in the Krebs cycle enzyme, fumarate
hydratase (FH), predispose affected individuals to
leiomyomas, renal cysts, and cancers, though the
respective pathogenic roles of mitochondrial and
cytosolic FH isoforms remain undefined. On the ba-
sis of comprehensive metabolomic analyses, we
demonstrate that FH1-deficient cells and tissues
exhibit defects in the urea cycle/arginine meta-
bolism. Remarkably, transgenic re-expression of
cytosolic FH ameliorated both renal cyst develop-
ment and urea cycle defects associated with renal-
specific FH1 deletion in mice. Furthermore, acute
arginine depletion significantly reduced the viability
of FH1-deficient cells in comparison to controls.
Our findings highlight the importance of extramito-
chondrial metabolic pathways in FH-associated
oncogenesis and the urea cycle/arginine metabolism
as a potential therapeutic target.
INTRODUCTION
Since first highlighted in the last century, altered metabolism has
been a consistent observation in cancer cells (Warburg, 1956).1440 Cell Reports 3, 1440–1448, May 30, 2013 ª2013 The AuthorsRecently, the identification of mutated Krebs cycle enzymes in
familial cancer syndromes has linked altered metabolism and
cancer directly (reviewed in Bayley and Devilee, 2010; Frezza
et al., 2011a). Mutations in one of these enzymes, fumarate hy-
dratase (FH), predispose individuals to hereditary leiomyomato-
sis and renal cell cancer (HLRCC) (Tomlinson et al., 2002).
Affected individuals also develop renal cysts, a phenotype that
is recapitulated in FH1 (murine FH)-deficient mice (Pollard
et al., 2007). Loss of FH activity results in accumulation of intra-
cellular fumarate, which, in turn, affects multiple signaling path-
ways, including inhibition of 2-oxoglutarate (2OG)-dependent
dioxygenase enzymes (Isaacs et al., 2005; Loenarz and Scho-
field, 2008; O’Flaherty et al., 2010; Pollard et al., 2005; Xiao
et al., 2012) and posttranslational modification (succination) of
cysteine residues (Adam et al., 2011; Alderson et al., 2006; Bar-
della et al., 2011; Yang et al., 2012). However, the mechanism(s)
of tumorigenesis and particularly the role of defective mitochon-
drial metabolism in FH-associated disease remain undeter-
mined. Though considered a Krebs cycle enzyme, FH is also
expressed in the cytosol and the nucleus (Yogev et al., 2010,
2011). Moreover, re-expression of cytosolic FH ameliorates
constitutive activation of both the hypoxia and antioxidant
response pathways in FH1-null cells, despite a persistent defect
in oxidative metabolism (Adam et al., 2011; O’Flaherty et al.,
2010). To investigate the role of extramitochondrial FH in renal
cyst development, we have undertaken high-resolution mass-
spectrometry-based metabolomic analyses of FH-deficient
cells, renal cysts, and tumors. To corroborate our findings in vivo,
we generated two transgenic murine models where either FH or
extramitochondrial FH (FHcyt) is stably expressed from the
Rosa26 locus (Zambrowicz et al., 1997).We demonstrate that re-
expression of cytosolic FH in FH1-deficient mice is critical for the
suppression of renal cyst development and restoration of
defects in the arginine biosynthesis pathway. Furthermore, FH-
deficient cells exhibit a greater dependence on exogenous argi-
nine than wild-type counterparts. Taken together, our data
support a role for extramitochondrial metabolic pathways in
renal neoplasia and arginine deprivation as a candidate target
for therapy.
RESULTS
Urea Cycle Metabolites Accumulate in FH1KO Kidneys
Previously, we demonstrated that mice with deletion of FH1 in
renal tubular epithelial cells (Shao et al., 2002) (FH1flox/flox Ksp-
Cre+/; FH1KO) develop hyperplastic renal cysts (Pollard et al.,
2007). This model has been characterized further by genetic
crosses and subsequent gene expression analyses (Adam
et al., 2011; Ashrafian et al., 2010), but without comprehensive
analysis of metabolism. Therefore, we determined metabolite
levels in control and FH1KO kidneys using capillary electropho-
resis time-of-flight mass spectrometry (CE-TOFMS; Soga et al.,
2009). Levels of fumarate, argininosuccinate, and citrulline were
increased significantly in FH1KO kidneys compared to controls,
whereas aspartate was depleted (Figures 1A–1D; Table S1).
Metabolic pathway analyses using IPA (Ingenuity Pathway Anal-
ysis, Ingenuity Systems) showed significant changes in the urea
cycle/arginine biosynthesis pathway (Table S1).
FH1KO Mouse Embryonic Fibroblasts Exhibit Multiple
Defects in the Krebs Cycle and Utilize the Urea Cycle,
but Not Reductive Carboxylation
There were at least two hypotheses to test: whether the urea
cycle is dysregulated in the FH1KO mouse embryonic fibro-
blasts (MEFs) as predicted above, and whether they use the
reductive carboxylation pathway as has been reported for other
FH-deficient cells (Mullen et al., 2012). Hence, we cultured wild-
type (FH1WT) and FH1KO MEFs in medium containing the sta-
ble isotope tracer glutamine-2,3,3,4,4-d5 ([D5]-glutamine) for 3
and 9 hr and determined the incorporation of deuterium label
in Krebs cycle and urea cycle metabolites by CE-TOFMS
analyses (Figure 1E; Table S1). Use of [D5]-glutamine by the ca-
nonical oxidative Krebs cycle would result in m+4 for 2OG and
succinate, m+2 for fumarate and malate, and m+1 for oxaloac-
etate and aspartate and thus provides a means of differentiating
whether argininosuccinate is generated by arginine and fuma-
rate, or alternatively by condensation of citrulline and aspartate
(Figure 1E). Significantly, we detected argininosuccinate m+2,
and, in addition, the isotopic distribution pattern of argininosuc-
cinate matched that of fumarate, but not of aspartate (Fig-
ure 1E). Therefore, we concluded that argininosuccinate is
synthesized directly from fumarate. The glutamine-dependent
reductive carboxylation pathway metabolizes 2OG to citrate
for lipid synthesis, forcing partial reversal of the Krebs cycle
(Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).
We did not observe evidence for a reversal of the Krebs cycle
in our MEF model, and furthermore, levels of citrate, cis-
aconitate, and isocitrate were significantly lower in FH1KOCcompared to FH1WT MEFs (Figure 1E; Table S1). We have
proposed previously that, in FH1KO MEFs, 2OG can be con-
verted to isocitrate by isocitrate dehydrogenase (IDH), but
isocitrate cannot be further metabolized to citrate, probably
as a result of impaired Aconitase 2 activity due to succination.
We did not observe any label in citrate and have suggested
that this may be the consequence of inactive aconitase in
both the mitochondria and cytoplasm of FH1KO MEFs (Ternette
et al., 2013).
Cytosolic FH Suppresses Renal Cyst Development
In Vivo
Given that the part of the urea cycle affected by fumarate accu-
mulation functions in the cytosol (Shambaugh, 1977), we
hypothesized that cytosolic FH may be important in the patho-
genesis of HLRCC. Previously, we demonstrated that expres-
sion of cytosolic FH in FH1KO MEFs reduced fumarate levels
significantly with concomitant loss of nuclear factor (erythroid-
derived 2)-like 2 (NFE2L2/NRF2) and hypoxia-inducible factor
(HIF) expression, but did not restore defects in oxidative meta-
bolism (Adam et al., 2011; O’Flaherty et al., 2010). To investi-
gate the in vivo role of cytosolic FH, we constructed two
transgenic mouse lines stably expressing either FH or FHcyt
(excluded from the mitochondria) with a C-terminal V5 affinity
tag and under the control of the CAG promoter (Niwa et al.,
1991). Equivalent expression between both lines was ensured
by targeting the FH transgenes to the Rosa26 locus (Zambro-
wicz et al., 1997) using integrase-mediated cassette exchange
(Chen et al., 2011) (Figures 2A and S1). Targeting fidelity
was assessed using PCR (Figure S1), and FH protein locali-
zation was confirmed in embryonic stem (ES) cells by immuno-
fluorescence (Figures 2B and 2C). Transgenic expression
of FH-V5 was analyzed by immunoblotting and immuno-
fluorescence (Figure S1). Similar to HLRCC patients with
renal cancer, mice with kidney-specific FH1 deletion develop
hyperplastic renal cysts (Pollard et al., 2007). We intercrossed
FH1KO mice with both transgenic lines (FH1KO+FH and
FH1KO+FHcyt). Macroscopic analyses of kidneys from 30-
week-old mice (Figure 2D) indicated that expression of either
transgene was sufficient to ameliorate the increased renal
mass in FH1KO mice, and microscopic analysis at three time
points (13, 20, and 30 weeks) confirmed that transgenic expres-
sion of cytosolic FH was sufficient to suppress cyst develop-
ment (Figures 2E–2H).
Cytosolic Expression of FH in FH1KO Mice Restores
Urea Cycle Metabolism
Since re-expression of cytosolic FH ‘‘rescued’’ the cystic pheno-
type associated with FH1 deletion, we hypothesized that this
might be mediated in part through alterations in metabolism.
Hence, we determined the metabolic consequences of restoring
cytosolic FH in FH1KO kidneys from 15-week-old mice by CE-
TOFMS and IPA analysis (Table S1). This time point was chosen
to avoid severe pathological changes in the kidneys and to
match previous analyses (Adam et al., 2011). Metabolites
showing themost significant changes are indicated using a heat-
map (Figure 3A). Notably, transgenic rescue of FH1 deficiency
with either FH or FHcyt restored levels of fumarate and urea cycleell Reports 3, 1440–1448, May 30, 2013 ª2013 The Authors 1441
Figure 1. FH-Deficient Cells Synthesize Argininosuccinate Directly from Fumarate
(A–D) Concentrations of specific urea cycle metabolites (mM) in control and FH1KO kidneys as determined by CE-TOFMS (Soga et al., 2009). All differences
between control and FH1KOmicewere significant (p < 0.01, Student’s t test). Formetabolomic analyses, sixmice aged 15weekswere analyzed from each group.
(E) CE-TOFMS analyses of deuterium label incorporation into key Krebs cycle and urea cycle metabolites in FH1WT (blue) and KO (red) MEFs after 9 hr incubation
in culture containing [D5]-glutamine. Transit of label through the canonical oxidative Krebs cycle would result in 2OG+4, succinate+4, fumarate+2, malate+2, and
Asp+1, while reductive carboxylation of glutamate would result in isocitrate m+2, citrate m+2, and aspartate m+1. We did not observe label enrichment in citrate,
so the reductive mechanism is not used for citrate synthesis. Argininosuccinate produced from arginine and fumarate has m+2, whereas that produced from
citrulline and aspartate hasm+1. We detected predominantly argininosuccinate m+2, which has a similar isotopomer distribution pattern to fumarate, suggesting
it is synthesized directly from fumarate.
For each graph, the concentration of metabolites (fmol/cell) is indicated on the y axis and label enrichment of [D5]-glutamine in FhWT and KO MEFs are
represented on the x axis in the following order: 12C, 12C-1d, 12C-2d, 12C-3d, and 12C-4d. See also Table S1 for absolute metabolite levels.
ACL, ATP citrate lyase; ACO1, -2, aconitase 1, -2; IDH1, -2, -3, isocitrate dehydrogenase 1, 2, 3; CS, citrate synthase; SUC, succinyl CoA synthetase; SDH,
succinate dehydrogenase; OGDH, oxoglutarate dehydrogenase; FH, fumarate hydratase; MDH, malate dehydrogenase; PDH, pyruvate dehydrogenase; GLS,
glutaminase; ASS, argininosuccinate synthase; ASL, argininosuccinate lyase; OCT, ornithine carbamoyltransferase; ARG, arginase.metabolites comparable to controls (Figures 3B–3E). Interest-
ingly, levels of citrulline (which exists in both the mitochondria
and cytosol) were not fully rescued in FH1KO+FHcyt animals
(Figure 3E).1442 Cell Reports 3, 1440–1448, May 30, 2013 ª2013 The AuthorsFumarate and Argininosuccinate Levels Are Increased
in HLRCC Tumors
To determine whether the increase in urea cycle metabolites
observed in FH1KO kidneys was recapitulated in FH mutant
Figure 2. Generation and Analyses of FH-
Expressing Transgenic Mice to Investigate
the Role of Cytosolic FH/Fumarate in Renal
Cyst Development
(A) The FH and FHcyt transgenes were cloned into
the CB92 vector and targeted to theRosa26 locus,
using phage-mediated recombination (Chen et al.,
2011).
(B and C) Localization of FH and FHcyt was
confirmed in ES cells by immunocytochemistry.
Colocalization (yellow) of FH (green) and mito-
chondria (red) is evident (B), whereas FHcyt is
absent from the mitochondria (C). Nuclei (blue) are
visualized with DAPI.
(D) Kidneys harvested from 30-week-old control,
transgene-only (FH, FHcyt), and genetically
‘‘rescued’’ mice (FH1KO+FH and FH1KO+FHcyt)
appeared macroscopically normal compared to
FH1KO kidneys, which appeared enlarged and
cystic.
(E) Hematoxylin and eosin (H&E) staining of kid-
neys harvested from mice at 13, 20, and 30 weeks
reveal that transgenic expression of either FH or
FHcyt is sufficient to ameliorate cyst development.
(F–H) Numbers and frequency of macrocysts
(>0.5 mm) and microcysts (>0.1 mm) were deter-
mined in each group (n = 6). Error bars represent
the SEM.
Scale bars, 5 mm (B and C), 10 mm (D), and 100 mm
(E). Error bars indicate SEM. See also Figure S1.
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Figure 3. Metabolite Analysis of Kidneys from FH1KO- and FH-Reconstituted Mice
(A) Heatmap showing relative levels of specific metabolites in kidneys from control, FH1 KO, and reconstituted (FH1 KO+FH and FH1 KO+FHcyt) mice. For each
group, kidneys from six mice (aged 15 weeks) were analyzed using CE-TOFMS (Soga et al., 2009), and the data were filtered to select only metabolites where
there was a 2-fold difference between any group and a p value <0.05 (one-way ANOVA). Relative metabolite levels are indicated by red (high) and green (low).
(B–E) Concentrations (mM) of the specific urea cycle metabolites fumarate (B), argininosuccinate (C), aspartate (D), and citrulline (E) measured in kidneys from
mice of each of the above four genotypes.
(F and G) Analysis of FH mutant renal cancers (n = 3) and adjacent normal tissue (n = 2) indicates accumulation of fumarate (F) and aspartate (G).
Error bars indicate SEM. See also Table S1.tumors, we usedCE-TOFMS and IPA to analyze themetabolome
of normal kidney (n = 2) and type 2 papillary tumors (n = 3) from
two HLRCC patients (Table S1). Increased levels of both fuma-
rate and argininosuccinate were observed in the tumors (Figures
3F and 3G).
Argininosuccinate Is Generated in FH-Deficient Cells via
Reversal of Argininosuccinate Lyase
Argininosuccinate can be generated either from citrulline and
aspartate (through argininosuccinate synthetase [ASS1]) or
from fumarate and arginine (through reversal of argininosucci-
nate lyase [ASL]) (Figure 1E; Wheatley, 2005). To confirm inde-
pendently the route by which argininosuccinate accumulates in
FH1 deficiency, we cultured WT and FH1KO MEFs in medium
containing uniformly labeled [U-15N4, U-
13C6] arginine and
analyzed the cells using heteronuclear single quantum correla-
tion nuclear magnetic resonance (HSQC-NMR) (Ludwig and
Gu¨nther, 2011). We observed labeled argininosuccinate in
FH1KO cells but not in WT cells (Figure 4A), consistent with a1444 Cell Reports 3, 1440–1448, May 30, 2013 ª2013 The Authorsreversed ASL reaction in these cells. We then analyzed two
panels of isogenic FH-deficient lines; FH1KOMEFs reconstituted
with either FH or FHcyt (O’Flaherty et al., 2010) and UOK262
(derived from a metastasis from an FH mutant renal cancer
(Yang et al., 2010b), which we have genetically complemented
with the same FH or FHcyt constructs (Figure S2). CE-TOFMS
analysis demonstrated that re-expression of either FH- or
FHcyt-suppressed fumarate (Figure 4B) and argininosuccinate
(Figure 4C) accumulation in both FH-deficient cell lines. We
observed argininosuccinate m+10 as the predominant iso-
topomer (Figure 4C), indicating the direct formation of arginino-
succinate from arginine and fumarate, thus corroborating the
data from the [D5]-glutamine labeling (Figure 1E).
FH-Deficient Cells Exhibit Increased Sensitivity to
Arginine Deprivation
Recent studies have demonstrated that depletion of arginine in
ASS1-negative tumors inhibits their growth and predicts clinical
benefit (Feun et al., 2012; Kelly et al., 2012; Yang et al., 2010a).
Figure 4. Argininosuccinate Is Produced from Arginine in FH-Deficient Cells
(A) Sections of HSQC spectra for the C4 (top panel) and C5 (bottom panel) resonances of arginine and argininosuccinate detected in FH1WT (red) and FH1KO
(blue) MEFs. Argininosuccinate was detected in FH1KO MEFs only, which also correlates with the appearance of the fumarate resonance at 6.5/138 ppm.
(B and C) Cells of the indicated genotype were cultured inmedia containing 15N4,
13C6-arginine for 12 hr prior tometabolite extraction and analyses of fumarate (B)
and argininosuccinate (C) levels by CE-TOFMS (Soga et al., 2009). The m+10 isotopomer comprises >90% of total argininosuccinate detected in FH1KO MEFs
and UOK262 cells, suggesting direct conversion of argininosuccinate from arginine and fumarate. Three independent cultures were used for each condition, and
data shown here are representative of two independent experiments.
(D–G) Concentrations (fmol/cell) of fumarate (B), argininosuccinate (C), citrulline (D), and aspartate (E) were determined in FH1WT and KO MEFs by CE-TOFMS,
confirming the metabolic profile observed in equivalent mouse kidneys of significantly elevated fumarate and argininosuccinate and significantly depleted
aspartate.
(H) The manganese-containing enzyme arginase catalyzes the conversion of arginine and water to ornithine and urea. Levels of arginine and ornithine (mM)
measured in medium by HPLC-MSMS following treatment with bovine arginase show that arginine levels are significantly reduced with time with a concomitant
increase in ornithine.
(I–L) WT and KO FH1 MEFs were cultured in medium treated with arginase for 1, 2, 4, and 6 hr compared to no treatment (0 hr). Cells were then returned to
standard DMEM (containing arginine) and assayed separately for proliferative capacity (I and J) and colony-forming capacity (K and L).
(I and J) Reduced proliferative capacity of FH1KOMEFs compared to WT controls is observed following culture in arginine-depleted medium for as little as 2 hr.
1.53 104 cells/well of 96-well plate were plated for each experimental group and measurements made using CyQuant. Fluorescence units were measured and
normalized to those of cells cultured in standard untreated medium.
(K) Representative photographs of colony assays for WT and KO FH1 MEFs 103 cells/10 cm plate were cultured for 10 days for each experimental group. Three
separate dilutions were plated for each experimental group, and the experiments were repeated in triplicate.
(L) The number of colonies formed by FH1WT and KO MEFs was counted and expressed relative to the colony count of cells cultured in standard untreated
medium (0 hr). The graph of plating efficiency versus time cultured in arginine-depletedmedium shows that FH1KOMEFs are acutely sensitive to reduced arginine
even for a very short time period (2 hr).
See also Figure S2.
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Given that FH-deficient cells exhibit a reversal of ASL activity in
the urea cycle, we hypothesized that transient arginine depletion
might selectively inhibit the growth of FH-deficient cells. Com-
parison of metabolite concentrations in FH1WT and KO MEFs
confirmed the profile observed in equivalent mouse kidneys, of
significantly elevated fumarate and argininosuccinate and signif-
icantly depleted aspartate (Figures 4D–4G; Table S1). Hence, we
cultured FH1KO and WT MEFs for 1, 2, 4, and 6 hr in standard
Dulbecco’s modified Eagle’s medium (DMEM) depleted of argi-
nine by addition of bovine arginase and then returned them to
standard DMEM. Since L-arginine is metabolized to L-ornithine
and urea by arginase (Shambaugh, 1977), the effectiveness
and time course of arginine depletion and parallel increase of
ornithine in the medium was confirmed by HPLC-MSMS (Fig-
ure 4H). The consequences of arginine depletion for cell prolifer-
ation and survival in colony assays were determined and show
clearly that culture of FH1KOMEFs for as little as 2 hr in medium
depleted of arginine results in loss of proliferative capacity,
which increases significantly with time (Figures 4I and 4J). Simi-
larly, there is a significant reduction in the number of FH1KO cells
surviving depletion of arginine from the culture medium to form
colonies compared to untreated cells or WT control MEFs (Fig-
ures 4K and 4L). This further confirms the dependence of
FH1KO MEFs on arginine for survival and growth.
DISCUSSION
Here, through global metabolite analyses, we have shown that
the urea cycle and arginine biosynthesis are significantly per-
turbed in FH-deficient cells, cysts, and tumors. Furthermore,
arginine biosynthesis occurs predominantly in the cytosol
(Salway, 1999) and therefore questions the relative role(s) of
mitochondrial and cytosolic FH in oncogenesis. To expand our
findings and to assess directly if cytosolic FH has a functional
role in vivo, we generated two FH-expressing transgenic mouse
lines (including a cytosolic variant, FHcyt), which we have previ-
ously demonstrated to suppress both HIF-1a and NRF2 expres-
sion in vitro despite a persistent defect in oxidative metabolism
(Adam et al., 2011; O’Flaherty et al., 2010). Remarkably, when
crossed with an established model of FH-associated cystic dis-
ease (Pollard et al., 2007), FHcyt ameliorated cyst development
and corrected defects in the urea cycle/arginine metabolism.
We hypothesized that FH-deficient cells may be auxotrophic
for arginine, a phenomenon often observed in ASS1-negative
cancers (Feun et al., 2008). Notably, favorable results have
been obtained from clinical trials using pegylated arginine deimi-
nase (ADI-PEG20; Feun and Savaraj, 2006) to treat ASS1-defi-
cient cancers including hepatocellular carcinoma and advanced
melanoma (Kuo et al., 2010). We were unable to obtain ADI-
PEG20 for this study and therefore used recombinant bovine
arginase (Dala and Szaja´ni, 1994) to deplete arginine acutely in
cell culture media. Whereas the viability of FH1KO MEFs was
dramatically reduced in comparison to wild-type cells, we did
not see the same differential effect between the HLRCC cell lines
UOK262 and UOK262+FH (reconstituted). Explanations for this
may be that the UOK262 cells are from a distant metastasis
and have been propagated extensively in vitro, or that the patient
may have received multiple rounds of therapy that have1446 Cell Reports 3, 1440–1448, May 30, 2013 ª2013 The Authorsimpacted themetabolism of these cells. Generation and analysis
of more primary HLRCC and control cell lines are required in or-
der to determine whether arginine depletion would be a suitable
therapeutic strategy for HLRCC. Alternatively, other arginase
types such as ADI-PEG20may bemore effective in the treatment
of human cell lines (Feun and Savaraj, 2006).
The recent identification of succinate dehydrogenase (SDH)
and FH as mitochondrial tumor-suppressor genes has provided
a direct link between dysfunctional mitochondria and cancer
(King et al., 2006). In contrast, data from our murine models of
early stage FH-associated disease indicate a more direct role
of fumarate, possibly acting as an oncometabolite (Ternette
et al., 2013). This hypothesis has striking parallels with the iden-
tification ofmutations in anothermetabolic enzyme IDH1, leading
to accumulation of 2-hydroxyglutarate identified as an oncome-
tabolite (Dang et al., 2009; Xu et al., 2011).
Although there are many similarities between FH-deficient
MEFs and the UOK262 human cell line, such as lactate produc-
tion and stabilization of HIF-1a (O’Flaherty et al., 2010; Sudar-
shan et al., 2009; Yang et al., 2010b), there are also clear
differences in their metabolism; for example, the reductive
carboxylation pathway is used by UOK262 cells (Mullen et al.,
2012) but is not utilized by either FH1KO MEFs or FH1-deficient
murine proximal tubular epithelial cells (Frezza et al., 2011b). It is
possible that the mouse and human cell lines are models for
different stages in the pathogenesis of HLRCC. We would sug-
gest that the FH1 mouse model (both in vivo and in vitro) is a
particularly valid model of the early stages of FH deficiency
that lead as far as cyst development in vivo, and that factors
yet to be defined may then act to drive cells toward neoplasia
and further dysregulated metabolism. However, studies using
the model have also highlighted pathways that are clearly
evident in FH-deficient human tumors, such as succination (Bar-
della et al., 2011), activation of the NRF2 antioxidant pathway
(Adam et al., 2011; Ooi et al., 2011), and, as indicated here, alter-
ation of urea cyclemetabolism. The UOK262 cell line perhaps re-
flects better the later stages of renal neoplasia and metastasis
associated with this. UOK262 are quite abnormal cells, and re-
expression of either FH or FHcyt, at least in our hands, exacer-
bates their abnormal morphology and, unlike reconstituted
MEFs, does not affect a full ‘‘rescue,’’ exemplified by incomplete
ablation of normoxic HIF-1a (Figure S2). It is also possible that
the UOK262 cells have acquired additional mutations subse-
quent to loss of FH activity.
The relatively low success rate in treating renal cancer has
been attributed in part to high levels of heterogeneity within tu-
mors (Fisher et al., 2012; Gerlinger et al., 2012; Yap et al.,
2012), and therefore treatment of HLRCC with arginase could
bemore effective if explored in combination with other therapies.
Thus, tumor and/or metastasis- derived cell lines such as
UOK262 will clearly reflect only a subset of the pathological fea-
tures of such heterogeneous renal cancers.
In summary, we have utilized a murine model of early HLRCC
to demonstrate that renal cyst development is independent of
mitochondrial FH activity. These studies have highlighted the
previously unrecognized importance of the urea cycle and argi-
ninemetabolism for FH-deficient cells and tumors and offer a po-
tential Achilles’ heel for such cells.
EXPERIMENTAL PROCEDURES
See Extended Experimental Procedures for additional information.
Generation of FH and FHcyt Transgenic Mice
The transgenic constructs consisted of the ubiquitous CAG promoter (Niwa
et al., 1991) driving the expression of either full-length (FH) or mitochondria
leader sequence deleted (-MLS) (FHcyt) human FH cDNA, both of which carried
a V5 tag at the C terminus (Figure 3A), together with a rabbit beta-globin poly-
adenylation sequence. The two transgenic constructs were cloned into a
PhiC31 integrase-mediated exchange vector, pCB92, which was assembled
by modifying pExchange4-CB9 (derived from pRMCE (Hitz et al., 2007)) with
a synthesized polylinker of unique sites to facilitate cloning. Integration of the
constructs occurred specifically at the ROSA26 locus via PhiC31 integrase-
mediated cassette exchange in murine IDG26.10-3 ES cells as previously
described (Chen et al., 2011). Correctly integrated ES cell clones were identi-
fied by PCR (Figure S1) and injected intomouseC57BL/6J blastocysts, and the
resulting chimeric males were mated to C57BL/6 females. Genotypes of trans-
genic F1 mice were established by PCR (Figure S1). All procedures were con-
ducted in keeping with AACR guidelines and under UK Home Office regula-
tions after approval by the Local Ethical Review process in Oxford University.
Human Tissue Samples
Anonymized human tumor and normal samples were collected with full ethical
approval (MREC 05\Q1605\66) as approved by the Oxford Centre for Histopa-
thology Research (OCHRe).
Statistics
All statistical analyses are indicated in the text in the relevant sections. One-
way ANOVA and t tests were performed using GraphPad Prism version 5.0d
for Macintosh (GraphPad Software, La Jolla, CA, http://www.graphpad.com).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, three
figures, and one table and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2013.04.006.
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